Staying Ahead of the Game
Nothing says “end of summer” like high school football practice, apple cider, and Halloween decorations. Everyone packs up their sand chairs and boogie boards and heads back to the classroom, or workplace, whichever is most applicable. Here at MJH Life Sciences®, where education and events go hand-in-hand, our studios have been polished up all summer to bring a series of medical education programs for our physician audience. Titles such as NSCLC Insights, CKD Stakeholder Summit, and Medical Crossfire®: Expert Insights in Anti-VEGF Dosing for nAMD and DME, are all intended to help physicians improve their patients’ outcomes.
On the Industry Sciences side, MJH strives to contribute to these efforts in a different way. We inform and educate those professionals who research new compounds, investigate potential therapies in clinical trials, manufacture and distribute these drugs, and who also inform patients and healthcare professionals (HCPs) on the most appropriate ways to take advantage of
innovative drugs.
Here, in addition to events, Industry Sciences offers webcasts, digitally-enhanced “books” and magazines, videos, podcasts, and other forms of educational material for our audiences.
Some current topics that may have relevance to clinical trial professionals when peeking ahead to potential commercial viability, especially those developing hopeful advanced and curative treatments, include:
The American Medical Association reports that overall health spending was 18.3% of GDP in 2021 compared with 19.7% of GDP in 2020. That figure was down a bit, but still represents a hefty piece of the pie. Of this, 31.1% went to hospital care, 14.9% to physician services, and 8.9% to prescription drugs.
Of course with any large enterprise, complexities abound. This complexity—a constantly evolving and moving target—ensures that learning new information must take precedence for all decision-makers. Please take advantage of our many resources as you head back to work and educate yourself on all the latest issues, challenges, and strategic guidance impacting your decisions.
Thank you for reading.
Mike Hennessy Jr. is the president and CEO of Applied Clinical Trials' parent company, MJH Life Sciences®
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
